News Hub | News Direct

COMCAST RISE AWARDS GRANT PACKAGES TO 100 SOUTHERN COLORADO SMALL BUSINESSES

Comcast Colorado

Today, Comcast announced the 100 businesses in Southern Colorado that will receive comprehensive grant packages, which include business consultation services, educational resources, a $5,000 monetary grant, creative production, media schedule, and a technology makeover. Comcast RISE is committed to supporting the growth of all small businesses, while advancing the objectives of diversity, equity, and inclusion, as well as community investment. The program was created to help businesses and their communities thrive, with a focus on economic growth. The regions in this round included Atlanta, Houston, Jacksonville, Richmond, VA and Southern Colorado. A total of 100 grants per city, or 500 grants overall, were announced today and will be awarded in September 2024. A sample of Southern Colorado grant recipients include: · RAD Hostel, Colorado Springs · ColorSplashPaintball, Pueblo · The Walter Brewing Company, Pueblo “RAD Hostel is all about creating an awesome Colorado experience for our guests. As our high ratings, awards, and guest reviews show, we are achieving our mission. However, we are lacking in getting the word out,” said Erin Welch, owner of RAD Hostel. “I'm honored and excited about being selected to receive this grant and I'm confident that with the marketing assistance and technology makeover, we can more effectively share the type of experience we offer, increase our occupancy, and ensure more happy guests have a RAD Colorado experience.” “I purchased this paintball business in March of 2019, and it was flourishing until the pandemic hit. I had to use all my capital just to keep the doors open. My planned projects and dreams were put on hold,” said Rique Lucero, owner of ColorSplashPaintball. “Thanks to Comcast RISE, I now have an opportunity for a fresh start, and resources to grow my business.” “Comcast is committed to supporting and empowering small businesses in our communities,” said J.D. Keller, senior vice president of Comcast’s Mountain West Region. “The Comcast RISE program will deliver innovative and impactful resources that will make a lasting impact on small businesses in Southern Colorado.” Comcast RISE was created in November 2020 to help small businesses hardest hit by COVID-19, from bakeries and barber shops to childcare centers and cleaning services, by providing the grants needed to survive and recover. The program has evolved from helping businesses survive the pandemic, to helping businesses and their communities thrive with a focus on economic growth. Grant packages include: COACHING SESSIONS - Business assessment and coaching that provide business owners with recommendations on how to help grow their businesses. EDUCATION RESOURCES - 12-month access to online entrepreneurship courses, learning modules and resources for small business owners. MONETARY GRANT - $5,000 monetary grant. CREATIVE PRODUCTION & MEDIA – Professionally produced 30-second TV commercial, plus a media strategy consultation and a 180-day linear media schedule. (Taxes and other fees may apply for production and media services.) TECHNOLOGY MAKEOVER - Computer equipment and Internet, Voice and Cybersecurity services for 12 months. (Taxes and other fees may apply for tech makeover services.) In addition, any small business owner can visit the Comcast RISE destination on X1 featuring aggregated small business news, tips, insights, and more. X1 customers can say “Comcast RISE” into the voice remote. Comcast RISE is part of Project UP, the company’s $1 billion commitment to advance digital equity through programs and community partnerships that connect people to the Internet, advance economic mobility and open doors for the next generation of innovators, entrepreneurs, storytellers and creators. More information is available at www.ComcastRISE.com. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Leslie Oliver +1 303-810-6326 leslie_oliver@comcast.com Company Website https://colorado.comcast.com/

August 13, 2024 11:51 AM Mountain Daylight Time

COMCAST RISE, A NATIONAL INITIATIVE TO SUPPORT AND STRENGTHEN SMALL BUSINESSES, AWARDS ANOTHER 100 HOUSTONIANS WITH COMPREHENSIVE GRANT PACKAGES

Comcast Texas

Today, Comcast announced the 100 businesses in the Greater Houston area that will receive comprehensive grant packages, which include business consultation services, educational resources, a $5,000 monetary grant, creative production, media schedule, and a technology makeover. The recipients are among more than 14,000 entrepreneurs nationwide who have been selected through the Comcast RISE program to date. Comcast RISE is committed to supporting the growth of all small businesses, while advancing the objectives of diversity, equity, and inclusion, as well as community investment. The program was created to help businesses and their communities thrive, with a focus on economic growth. The regions in this round included Atlanta, Houston, Jacksonville, Richmond, VA and southern Colorado. 100 grants per city, or 500 grants overall, were announced today and will be awarded in September 2024. A sample of Houston’s grant recipients include Red Circle Ice Cream in southwest Houston, and Miyagi Ken International Karate Academy in Spring. “I’m speechless. As a small business, this means the world to us,” said Nickey Ngo, owner of Red Circle Ice Cream. “We’re a small mom and pop ice cream shop, doing everything by ourselves. I feel like I won the lottery. Comcast RISE will help grow my business and keep up with the competition.” “Supporting small businesses means investing in the heart of our communities,” said Loren Hudson, SVP and Chief Diversity Officer, Connectivity and Platforms, Comcast. “By empowering entrepreneurs and small business owners with the skills and resources they need to grow and succeed, we help ensure our local neighborhoods can flourish and thrive too.” Comcast RISE was created in November 2020 to help small businesses hardest hit by COVID-19, from bakeries and barber shops to childcare centers and cleaning services, by providing the grants needed to survive and recover. The program has evolved from helping businesses survive the pandemic, to helping businesses and their communities thrive with a focus on economic growth. Grant packages include: COACHING SESSIONS - Business assessment and coaching that provide business owners with recommendations on how to help grow their businesses. EDUCATION RESOURCES - 12-month access to online entrepreneurship courses, learning modules and resources for small business owners. MONETARY GRANT - $5,000 monetary grant. CREATIVE PRODUCTION & MEDIA – Professionally produced 30-second TV commercial, plus a media strategy consultation and a 180-day linear media schedule. (Taxes and other fees may apply for production and media services.) TECHNOLOGY MAKEOVER - Computer equipment and Internet, Voice and Cybersecurity services for 12 months. (Taxes and other fees may apply for tech makeover services.) In addition, any small business owner can visit the Comcast RISE destination on X1 featuring aggregated small business news, tips, insights, and more. X1 customers can say “Comcast RISE” into the voice remote. Comcast RISE is part of Project UP, the company’s $1 billion commitment to advance digital equity through programs and community partnerships that connect people to the Internet, advance economic mobility and open doors for the next generation of innovators, entrepreneurs, storytellers and creators. More information is available at www.ComcastRISE.com. Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Ilona Carson +1 346-624-2074 ilona_carson@comcast.com Company Website https://houston.comcast.com/

August 13, 2024 11:06 AM Central Daylight Time

Image

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

MarketJar

Major Depressive Disorder (MDD) was the third leading cause of global disease burden in 2008, according to the World Health Organization, with projections that it could become the leading cause by 2030. MDD is a severe mental health condition marked by persistent sadness, loss of interest in activities, and difficulties in daily functioning. 1 Lithium, a well-known mood stabilizer, has been used off-label for MDD, but its application is limited by safety concerns due to its narrow therapeutic window. In response to this unmet need, Alzamend Neuro, Inc. (NASDAQ:ALZN), a clinical-stage biopharmaceutical company, is dedicated to developing innovative treatments for neurological and psychiatric disorders, including MDD. The company's latest effort involves a promising partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001, a next-generation lithium-based therapeutic candidate aimed at improving the safety and effectiveness of lithium treatment for MDD. Dr. Ovidiu Andronesi, an Associate Professor of Radiology at Harvard University, will lead the study. This trial aims to compare AL001's effectiveness and safety against a marketed lithium carbonate product by examining lithium levels in the brain and its structures. Alzamend Neuro, Inc. (NASDAQ:ALZN) previously completed a Phase IIA trial that identified a maximum tolerated dose (MTD) for AL001. This dose is designed to provide lithium at a safe and effective level without the need for frequent monitoring, unlike current lithium treatments that are limited by chronic toxicity and poor physicochemical properties. The primary goal of this study is to determine the ideal dose of AL001 that can achieve similar or better effectiveness and safety compared to existing lithium salts. Alzamend is optimistic that the study will meet regulatory safety standards through the FDA's Section 505(b)(2) pathway, which allows for new formulations of approved drugs. Stephan Jackman, Chief Executive Officer of Alzamend Neuro, Inc. (NASDAQ:ALZN), expressed enthusiasm about the partnership with Massachusetts General Hospital and Dr. Andronesi for the pivotal study of AL001. He highlighted the potential of AL001 to be a next-generation lithium product with an improved safety profile and enhanced brain biodistribution, which could eliminate the need for routine therapeutic drug monitoring (TDM). Jackman emphasized that developing such a product would represent a significant advancement over existing lithium-based treatments and could have a positive impact on the over 21 million Americans affected by Major Depressive Disorder (MDD). Alzamend plans to share more details about the study’s timeline and market opportunities in the near future. Alzamend Neuro and Massachusetts General Hospital Launch Phase II Trials of AL001 for Bipolar Disorder and Alzheimer’s Alzamend Neuro, Inc. (NASDAQ:ALZN) is also partnering with MGH to conduct Phase II clinical trials of AL001 for patients with bipolar disorder (BD) and Alzheimer’s disease. These trials are also led by Dr. Ovidiu Andronesi, an Associate Professor of Radiology at Harvard University. Lithium, the first mood stabilizer approved by the U.S. Food and Drug Administration (FDA), remains the gold standard for treating bipolar disorder (BD). With over 35 years of use, its safety profile is well established, which may reduce regulatory hurdles. This trial aims to compare the increase in brain lithium levels between AL001 and a commonly marketed lithium salt in BD patients, seeking to optimize dosing for enhanced effectiveness and safety. As for the Alzheimer’s trial, a cohort of healthy subjects will be studied to compare their plasma and brain pharmacokinetics with those of Alzheimer's patients. This trial aims to evaluate the increase in brain lithium levels and its distribution between AL001 and a commonly marketed lithium salt in both Alzheimer's patients and healthy subjects. Alzamend Neuro Secures $25 Million Funding to Advance Clinical Trials Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the initial two tranches under a $25 million purchase agreement. This investment will drive the progress of Alzamend 's clinical trials and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman highlighted the company’s commitment to achieving clinical milestones and transforming lithium-based therapies for millions of people affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.ncbi.nlm.nih.gov/books/NBK559078/ Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 12, 2024 09:30 AM Eastern Daylight Time

Image

Back to School Ready 2024

News Media Group, Inc.

Contact Details News Media Group, Inc. Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/

August 08, 2024 01:33 PM Eastern Daylight Time

Video

Anthony Milewski Unveils Monthly Newsletter for Mastering Market Speculation

MarketJar

The Oregon Group just announced the launch of its latest initiative: "Greed, Guts and Glory: Mastering the Art of Speculation." This monthly newsletter, authored by the group's founder, Anthony Milewski, brings a wealth of experience, insight, and strategy directly to the desks of speculators and investors worldwide. Introducing "Greed, Guts and Glory" The commodities market is notoriously complex and volatile. Navigating this challenging environment requires more than just knowledge—it demands experience, intuition, and a deep understanding of market dynamics. Anthony Milewski, a seasoned investor with decades of experience in the commodities sector, understands this better than most. His new newsletter, "Greed, Guts and Glory," is not just a collection of market insights; it's a comprehensive guide designed to equip investors with the tools they need to thrive in this high-stakes arena. Hosted on The Oregon Group platform, this newsletter is more than just a publication—it's a community. "Greed, Guts and Glory" aims to foster a network of like-minded speculators, providing a space where ideas can be exchanged, strategies refined, and market victories celebrated. The Strategic Vision Behind the Newsletter The launch of "Greed, Guts and Glory" aligns with The Oregon Group 's broader mission to provide unparalleled investment research and thought leadership in the commodities and energy sectors. By creating a platform for direct communication between Anthony Milewski and the global investment community, The Oregon Group is not only expanding its reach but also reinforcing its position as a leader in the field. The key objective of this initiative is to raise awareness about the unique opportunities and challenges within the commodities market. By offering a blend of market analysis, strategic insights, and personal anecdotes, the newsletter is designed to attract a diverse audience—from seasoned investors to newcomers eager to learn the ropes. Anthony's approach to this new venture is encapsulated in his own words: “Trading has no time for niceties, just greed, guts, and glory. So as the old adage goes, 'if you want to do something new, you have to stop doing something old.'" This sentiment reflects the bold, forward-thinking philosophy that has always been at the core of The Oregon Group 's operations. What Subscribers Can Expect "Greed, Guts and Glory" promises to deliver a wealth of content each month, tailored to meet the needs of its readers. Key features of the newsletter include: Insights and Strategies: Drawing on his extensive experience, Anthony will share his thoughts on the current state of the commodities market, providing readers with actionable insights and effective strategies to navigate its complexities. Market Opportunities: The newsletter will highlight emerging opportunities within the commodities sector, offering subscribers a chance to stay ahead of the curve in a rapidly changing landscape. Community Engagement: One of the newsletter's most unique aspects is its emphasis on community. Subscribers will have the opportunity to engage with Anthony and each other, fostering a collaborative environment where ideas and experiences can be shared. Personal Anecdotes and Lessons: Anthony's journey in the commodities market has been marked by both successes and challenges. In "Greed, Guts and Glory," he will share personal stories and lessons learned, providing valuable context and inspiration for readers. Anthony Milewski: A Leader in Commodities Investment Anthony Milewski is no stranger to the world of commodities. With a career spanning several decades, he has served as a founder, advisor, director, executive, and investor across a variety of commodities, jurisdictions, and companies. His involvement in financing deals that have raised billions of dollars speaks to his deep understanding of market dynamics and his ability to identify and capitalize on key investment opportunities. Anthony's decision to launch "Greed, Guts and Glory" is a testament to his commitment to sharing his knowledge and experiences with the next generation of investors. Reflecting on his journey, Anthony recalls a story about Henry Ford, who chose to retain an employee despite a costly mistake, valuing the lessons learned over the financial loss. This anecdote resonates with Anthony's own philosophy, where he views each market experience—whether a win or a loss—as an opportunity for growth. A New Era for The Oregon Group The launch of "Greed, Guts and Glory" marks a new era for The Oregon Group. By leveraging Anthony Milewski's extensive experience and thought leadership, the company is poised to become an even more influential player in the commodities and energy sectors. The newsletter is not just a source of information; it's a strategic tool designed to empower investors, foster community, and drive success in the commodities market. As the commodities market continues to evolve, so too does The Oregon Group. With "Greed, Guts and Glory," the company is not only providing valuable insights but also building a community of investors who are ready to take on the challenges and opportunities of the future. To stay connected with Anthony Milewski, visit www.anthonymilewski.com or follow him on Twitter/X. Follow The Oregon Group on LinkedIn and Twitter. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, The Oregon Group. Market Jar Media Inc. has or expects to receive from The Oregon Group’s Digital Marketing Agency of Record (Native Ads Inc) one thousand five hundred USD for this article. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PressReach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PressReach.com 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding The Oregon Group.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to The Oregon Group.’s industry; (b) market opportunity; (c) The Oregon Group’s business plans and strategies; (d) services that The Oregon Group intends to offer; (e) The Oregon Groups milestone projections and targets; (f) The Oregon Group’s expectations regarding receipt of approval for regulatory applications; (g) The Oregon Group’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) The Oregon Group’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute The Oregon Group’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) The Oregon Group’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) The Oregon Group’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) The Oregon Group’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of The Oregon Group to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) The Oregon Group’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact The Oregon Group’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing The Oregon Group’s business operations (e) The Oregon Group may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, The Oregon Group undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does The Oregon Group nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither The Oregon Group nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of The Oregon Group or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of The Oregon Group or such entities and are not necessarily indicative of future performance of The Oregon Group or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 08, 2024 10:00 AM Eastern Daylight Time

Image

THE WORLD’S FIRST IMMERSIVE GAMING EXPERIENCE TO LAUNCH SECOND HOUSTON LOCATION THIS AUGUST

Activate

Activate, the pioneering live-action gaming venue and viral sensation on TikTok, is thrilled to announce the grand opening of its second location in Houston on August 16, 2024, after a successful opening in Katy. This unique and dynamic venue offers guests the chance to immerse themselves in the nationwide gaming phenomenon. Activate The Woodlands is located at 536 Sawdust Rd, Suite C, Spring, TX 77380. Activate is revolutionizing the gaming landscape, extending its reach across the United States with 40 successful locations worldwide and an unstoppable momentum. Boasting a global player base of over 2.5 million, this exciting experience combines cutting-edge technology with thrilling challenges, providing an electrifying social adventure. "Activate is excited to expand its footprint by opening a second location in Houston to meet the growing demand for immersive, interactive experiences among residents and visitors,” says Will Gray, Director of Marketing at Activate. "This new venue will allow a broader audience to experience the unique mix of physical activity and digital gaming that Activate is known for. We're excited to bring this thrill to a new market and engage more adventurers.” From August 23 to 25, Activate is hosting its Grand Opening Weekend with special surprises, the likes of which they have never done before. The new venue will offer a broader audience the opportunity to enjoy the unique blend of physical activity and digital gaming that Activate is renowned for. Activate The Woodland's cutting-edge gaming facility invites players of all ages and skill levels to explore and create their own unique gaming experiences. Here’s what to expect: Guests can sign up in groups of two to five players Through progress tracking via Activate’s high-tech electronic RFID wristbands, players can rack up points, leveling up and earning prizes along the way. Top gaming rooms include the TikTok viral sensation Mega Grid with 500+ multi-activated rainbow-coloured tiles, blasting the beaming bullseye in a game called Strike, and feel like a modern day spy in the Laser room. Try Level 1 easy or take it to Level 10 extreme. Play as a team in cooperative mode, or challenge your friends in competitive mode games. Additional Activate locations are set to open in 2024 across the U.S. in markets such as Columbus, Detroit, St. Louis, a third location in the Dallas Fort Worth Metroplex, Cleveland, and New York City, along with internationally in the UK and UAE. Today, Activate operates over 40 locations across Canada and the U.S. PLAN YOUR VISIT Wear activewear and flat, closed-toe shoes. Where: 536 Sawdust Rd., Suite C, Spring, TX 77380. When: Monday through Thursday, 10 a.m. to 10 p.m. | Friday, 10 a.m to 11 p.m | Saturday, 9 a.m. to 11 p.m. | Sunday, 9 a.m. to 10 p.m. Cost: Starting at 19.99 per player Mon-Thurs and 24.99 per player Fri-Sun (And Holidays) For a sneak peek into Activate’s action-packed gaming experience, click here. Click here for high-res assets ### Activate is the world's first active gaming experience where players #EnterTheGame. Activate offers a unique blend of physical activity and gaming that promotes a healthy lifestyle. Each Activate location provides fun and interactive rooms for players to compete, earn stars and track achievements. With the global headquarters located in Winnipeg, Canada, Activate has grown to 40 locations across Canada, and the U.S. To join the active gaming movement, visit Activate and follow on social media: Facebook: Activate Instagram: @activategames TikTok: @activategames Contact Details Jive PR + Digital Jalila Singerff +1 613-614-6777 jalila@jiveprdigital.com Company Website https://playactivate.com

August 08, 2024 09:00 AM Eastern Daylight Time

The Highly Anticipated NILU Hypercar has Arrived!

Nilu

Nilu27, the hypercar brand recently founded by celebrated sports car designer Sasha Selipanov, is thrilled to showcase its first vehicle: the self-titled NILU hypercar. Following a number of social media teasers, which created a stir among the sports car community, the car can finally be revealed in its entirety. The NILU hypercar challenges traditional automotive industry trends. By avoiding electrification, digitalization, and other technological aids, NILU will deliver a raw, unfiltered, uncensored driving experience. Taking inspiration from sources such as ’60s F1 and Le Mans racers, classic Italian design houses, the Bauhaus “form follows function” philosophy, old school American muscle, drift cars, mathematics, and avant garde metal music, NILU’s no-nonsense design is as eclectic as it is original. Sasha’s goal was to create a car with an “inevitable” design: fresh and yet somehow familiar. The resulting NILU exterior, with its tight cross sections and sinuous curves, is functional, lean and aerodynamic. For maximum contrast, it juxtaposes clean sculptural surfaces with its mechanical, exposed and intricately detailed engine bay. True to Bauhaus philosophy, NILU eschews superfluous styling features to celebrate essential functional beauty. The NILU chassis features a bespoke carbon fiber monocoque with lightweight aluminum-alloy tubular subframes. In contrast to “fashionable” composite subframes, the designer deliberately chose a tubular approach to improve access to the drivetrain components while effortlessly facilitating heat extraction and celebrating the mechanical aesthetic. The NILU cabin was designed to provide perfect viewing angles with ideal ergonomics and safety. The designer was able to achieve an incredibly low roofline and compact cabin dimensions without sacrificing comfort. NILU seats two adults in a traditional side-by-side layout with best-in-class ingress and egress made possible by substantial gullwing doors, low sill heights, and fixed, sunken seats, which do not obstruct the door apertures with their side bolsters. The NILU human/machine interface is all about manual, analog controls, inputs and feedback. The only screen is the rear view camera/mirror, which addresses the traditional weakness of mid-engined sports cars: the lack of rearward visibility. The steering wheel’s compact size and perfectly round shape allows for incredibly detailed steering feel and input precision. The wheel is void of switches, buttons and toggles; a testament to the belief that performance driving requires full concentration with zero distractions. Gone are the driving modes, settings and options: NILU controls are both primary and intuitive. For this reason, an open-gate, seven-speed manual transmission celebrates raw, analog driving while adding a safety element with its reverse gear lock-out. Steering wheel, pedal box, headrest, door mirrors and other adjustments are deliberately manual, accessed by gratifying manual levers and switches. The tactile, haptic feedback from cold-touch, machined billet controls was deemed both more engaging and, crucially, safer than navigating through screen menus. PRODUCTION The NILU hypercar is Sasha’s vision in its purest form; a vision he’s been perfecting since 2006. It will initially be available in an extremely limited run with production capped at 15 units. “ My path in the industry has never been about following rules and sticking to norms,” Sasha explained. “I was never afraid to follow my intuition or chase my dreams. Breaking conventions is simply a byproduct. The same is true for NILU – a hypercar that discards current trends and conventions in pursuit of an elevated automotive experience. “Unveiling NILU to the world is a dream come true; a moment so profound it is hard to express in words. The vision was the result of a decades-long search, sleepless nights, years of overthinking and overanalyzing. I was fortunate to learn from and contribute to the industry’s best; now my team and I are thrilled to put all this vision and knowledge into action.” V12 ENGINE Nilu27 has partnered with Hartley Engines in New Zealand to produce one of the most powerful and visually striking naturally aspirated engines in the world. The NILU engine bay is fully exposed, showcasing the beautiful 6.5-liter, 80-degree V12. As NILU will not rely on electrification, it aims to be the world’s most powerful, naturally aspirated hypercar. To achieve this, the V12 will deliver more than 1000 horsepower. And while its large bore and short stroke will make it rev like an electric motor, the even-fire engine will provide the driver with the perfect amount of tactile vibration. The Hartley V12 has a refined combustion area, high-flow ports, and performance-style valve geometry: something OEMs typically cannot accommodate in their compact platforms. The engine also features 12 large, individual throttle bodies for instant throttle response. Another key differentiator for the NILU V12 is its unique “Hot V.” In this configuration, the conventional exhaust and intake positions are swapped around. The setup delivers key advantages when it comes to packaging, heat extraction, and aesthetics. And it has allowed the stunning “snakepit” 12-into-1 exhaust headers to serve as a unique highlight of the exterior design. The entire exhaust system was 3D-printed in Inconel, allowing the complex design to be realized; another unique feature when you consider its dimensions. Mated to the seven-speed CIMA manual transmission, and housed in the ceramic-coated aluminum-alloy subframe, the NILU V12 represents functional beauty at its finest. Nelson Hartley, founder and CEO of Hartley Engines, said, “We’ve been quietly working on the design and layout of our own engine for the last few years, taking inspiration from late ’80s and early ’90s Formula 1 cars. We strove for the kind of engineering that’s raw, endearing, emotional, and sometimes a little crazy. “With Sasha’s wishlist for NILU, we finally found the perfect project to dedicate our time and were able to adapt our development into his Hot V configuration, designing the engine around his chassis layout. “Make no mistake; this is not an OEM engine from another manufacturer converted to the Hot V; this is a bespoke, large bore, short stroke monster. It’s got aggressive cams, aggressive port flow, lightweight components and exotic materials. We want to get a cold sweat every time the V12 starts and revs. It’s fair to say, we’re very excited!" DYNAMICS The NILU hypercar employs a double wishbone, pushrod suspension, with its extremely long wishbones visible from the rear; the length contributing to the exceptionally precise and compliant handling characteristics. A set of Michelin Pilot Sport Cup 2 R tires were fitted, specified at 265/35 R20 front and 325/30 R21 rear. They have been mounted to 10x20” and 13x21” Nilu27 centerlock wheels, which were designed in-house with intricate lightweight detailing to reduce the unsprung weight. The wheels are produced by AppTech in Italy. Carbon-ceramic braking equipment was sourced from Brembo. The Italian company’s GT | BM calipers are fitted front and rear in a custom white finish. The car also has Brembo’s highest performance CCM-R Plus rotors, which deliver outstanding performance and fade resistance. THE FUTURE The initial NILU prototype vehicles and first batch of customer cars will be assembled by Aria Group in Irvine, CA, allowing Nilu27 to ramp-up its own facilities overseas. Nilu27 is simultaneously developing a street homologated version. This variant will be limited to 54 units, four of which will be unique, one-off designs. “We’ve been fascinated by the strong reaction to our social media teasers alone,” said Inna Selipanov, the company’s Co-Founder and COO. “While the world is moving towards electrification, and for very good reason, we firmly believe the timelessness of these cars will not only keep them relevant but they will continue to find a place in the collections of passionate car lovers.” Nilu27 is proud to have the support of industry leaders such as Aerotak, AppTech, Aria Group, Brembo, CIMA, Hartley Engines, Michelin, and Schroth. The car will be unveiled to a select VIP and media group at a private Los Angeles event on August 8. Its public debut will follow on August 15 on the ramp at Pebble Beach in Monterey, California, before appearing on the Concept Lawn at the Pebble Beach Concours d’Elegance on August 18. The NILU hypercar will also debut in CSR Racing 2; the hyper-real mobile racing game from Zynga’s NaturalMotion. Players can experience the high-octane performance and stunning in-game design this November. EDITOR’S NOTE Images for editorial use are available here: https://www.dropbox.com/scl/fo/slb7tdet19fb5pomdq8vo/AJPBTh72JpXxQSJDFwZA6JI?rlkey=4cn745k7vb2sxs4fmlfwwk5gb&dl=0 Please contact us if high-resolution images are required for print. A NILU video is available to view and share here: https://youtu.be/2gbQEQwedr8 ABOUT Nilu27 Founded in 2024 by Sasha and Inna Selipanov, Nilu27 is on a mission to produce quintessential sports cars that will withstand the test of time. With a primary focus on a visceral driving experience, the company’s purpose is to celebrate all elements of the car that engage the senses, which means divorcing from technology in certain instances. We’re car people; we build cars for people who love cars. For more information, please visit nilu27.com Contact Details Greg Emmerson, The ID Agency greg@theidagency.com Company Website https://www.nilu27.com/

August 07, 2024 05:55 AM Pacific Daylight Time

Image

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

MarketJar

Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide. 1 Rising cases has led to an uptick in new treatments moving through the clinical stages, including Alzamend Neuro, Inc. (NASDAQ:ALZN), which is focused on developing next-generation treatments for Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Among its promising pipeline, AL001 stands out as a potential game-changer for bipolar disorder treatment. Alzamend Neuro 's AL001, a patented ionic cocrystal technology, aims to deliver lithium in a way that reduces toxicity while maintaining therapeutic efficacy by combining lithium, salicylate, and L-proline. Alzamend Neuro is rapidly advancing treatments for mental health disorders, potentially accelerating clinical phase progress due to the successes of AL001 in a Phase I and Phase IIA clinical trials for the treatment of Alzheimer’s. In 2023, the company filed IND applications for Phase IIA Clinical Trials of AL001 for Bipolar Disorder, MDD and PTSD. By the end of 2023, the FDA granted approval for these studies via “Study may proceed” letters. Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder On August 6th, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced a partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001 for treatment of patients with bipolar disorder. MGH, the primary clinical education and research facility of Harvard Medical School, is the world's largest hospital-based research program. Dr. Ovidiu Andronesi MD, PhD, Associate Professor of Radiology at Harvard University and Director of Multinuclear Metabolic Imaging at the Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, will lead the study as the Principal Investigator. The trial will compare AL001 to a marketed lithium carbonate product, focusing on bioavailability and brain distribution of lithium, with the goal of establishing AL001's safe, effective, and tolerable dosing requirements. AL001 is designed to offer the therapeutic benefits of traditional lithium salts while minimizing their toxic side effects. This head-to-head study will measure lithium levels in the brain and structures of bipolar disorder patients, building on mouse studies that suggest AL001 can achieve therapeutic benefits at lower doses. The study will also leverage brain imaging to predict the efficacy and safety of AL001 compared to existing lithium treatments. Alzamend Neuro 's previous Phase IIA studies of AL001 in Alzheimer's patients and healthy subjects have demonstrated a benign safety profile, identifying a candidate dose unlikely to require therapeutic drug monitoring (TDM). This is a significant advancement, as current lithium treatments require rigorous monitoring due to their narrow therapeutic window and potential toxicity. “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Alzamend Neuro, Inc. (NASDAQ:ALZN) CEO Stephan Jackman, “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require therapeutic drug monitoring (TDM), it would constitute a major improvement over current lithium-based treatments and positively impact the 7+ million Americans afflicted with bipolar disorder. We look forward to providing more details regarding study timelines and market opportunity in the near future.” This innovation has the potential to positively impact the over 7 million Americans living with bipolar disorder. Further details about the study timelines and market potential will be shared soon. Alzamend Neuro to Conduct a Phase II Clinical Trial of AL001, involving Patients with Alzheimer’s Disease Alzamend Neuro, Inc. (NASDAQ:ALZN) also just announced a collaboration with Massachusetts General Hospital (MGH) to conduct A Phase II clinical trial for AL001, for the potential treatment of Alzheimer's disease. This trial will involve both Alzheimer’s patients and healthy subjects to compare the bioavailability and brain distribution of AL001 versus a marketed lithium carbonate product. The trial, which will also be led by Dr. Ovidiu Andronesi of Harvard University, aim to establish AL001's safe, effective, and tolerable dosing requirements. The potential to avoid the need for therapeutic drug monitoring (TDM) is also significant, as it could simplify treatment regimens and improve patient compliance. By potentially offering a safer and more effective alternative to traditional lithium treatments, AL001 could revolutionize how Alzheimer's disease is managed. The ability to measure lithium levels directly in the brain and brain structures using advanced imaging techniques will provide invaluable insights into the drug’s efficacy and safety. This approach not only enhances our understanding of how AL001 works but also supports its potential approval through a Section 505(b)(2) pathway with the FDA. If successful, the trial could pave the way for a new era in Alzheimer's treatment, providing hope for millions of patients and their families. Financial Support for Clinical Trial In addition to this groundbreaking partnership, Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the first two tranches of a $25 million Series A purchasing agreement. This investment supports the advancement of Alzamend 's clinical trial and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman emphasized the company's dedication to advancing clinical milestones and revolutionizing lithium-based therapies for millions affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.who.int/health-topics/mental-health#tab=tab_2 Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 06, 2024 11:45 AM Eastern Daylight Time

Image

Headline

MarketJar

Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide. 1 Rising cases has led to an uptick in new treatments moving through the clinical stages, including Alzamend Neuro, Inc. (NASDAQ:ALZN), which is focused on developing next-generation treatments for Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Among its promising pipeline, AL001 stands out as a potential game-changer for bipolar disorder treatment. Alzamend Neuro 's AL001, a patented ionic cocrystal technology, aims to deliver lithium in a way that reduces toxicity while maintaining therapeutic efficacy by combining lithium, salicylate, and L-proline. Alzamend Neuro is rapidly advancing treatments for mental health disorders, potentially accelerating clinical phase progress due to the successes of AL001 in a Phase I and Phase IIA clinical trials for the treatment of Alzheimer’s. In 2023, the company filed IND applications for Phase IIA Clinical Trials of AL001 for Bipolar Disorder, MDD and PTSD. By the end of 2023, the FDA granted approval for these studies via “Study may proceed” letters. Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder On August 6th, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced a partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001 for treatment of patients with bipolar disorder. MGH, the primary clinical education and research facility of Harvard Medical School, is the world's largest hospital-based research program. Dr. Ovidiu Andronesi MD, PhD, Associate Professor of Radiology at Harvard University and Director of Multinuclear Metabolic Imaging at the Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, will lead the study as the Principal Investigator. The trial will compare AL001 to a marketed lithium carbonate product, focusing on bioavailability and brain distribution of lithium, with the goal of establishing AL001's safe, effective, and tolerable dosing requirements. AL001 is designed to offer the therapeutic benefits of traditional lithium salts while minimizing their toxic side effects. This head-to-head study will measure lithium levels in the brain and structures of bipolar disorder patients, building on mouse studies that suggest AL001 can achieve therapeutic benefits at lower doses. The study will also leverage brain imaging to predict the efficacy and safety of AL001 compared to existing lithium treatments. Alzamend Neuro 's previous Phase IIA studies of AL001 in Alzheimer's patients and healthy subjects have demonstrated a benign safety profile, identifying a candidate dose unlikely to require therapeutic drug monitoring (TDM). This is a significant advancement, as current lithium treatments require rigorous monitoring due to their narrow therapeutic window and potential toxicity. “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Alzamend Neuro, Inc. (NASDAQ:ALZN) CEO Stephan Jackman, “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require therapeutic drug monitoring (TDM), it would constitute a major improvement over current lithium-based treatments and positively impact the 7+ million Americans afflicted with bipolar disorder. We look forward to providing more details regarding study timelines and market opportunity in the near future.” This innovation has the potential to positively impact the over 7 million Americans living with bipolar disorder. Further details about the study timelines and market potential will be shared soon. Alzamend Neuro to Conduct a Phase II Clinical Trial of AL001, involving Patients with Alzheimer’s Disease Alzamend Neuro, Inc. (NASDAQ:ALZN) also just announced a collaboration with Massachusetts General Hospital (MGH) to conduct A Phase II clinical trial for AL001, for the potential treatment of Alzheimer's disease. This trial will involve both Alzheimer’s patients and healthy subjects to compare the bioavailability and brain distribution of AL001 versus a marketed lithium carbonate product. The trial, which will also be led by Dr. Ovidiu Andronesi of Harvard University, aim to establish AL001's safe, effective, and tolerable dosing requirements. The potential to avoid the need for therapeutic drug monitoring (TDM) is also significant, as it could simplify treatment regimens and improve patient compliance. By potentially offering a safer and more effective alternative to traditional lithium treatments, AL001 could revolutionize how Alzheimer's disease is managed. The ability to measure lithium levels directly in the brain and brain structures using advanced imaging techniques will provide invaluable insights into the drug’s efficacy and safety. This approach not only enhances our understanding of how AL001 works but also supports its potential approval through a Section 505(b)(2) pathway with the FDA. If successful, the trial could pave the way for a new era in Alzheimer's treatment, providing hope for millions of patients and their families. Financial Support for Clinical Trial In addition to this groundbreaking partnership, Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the first two tranches of a $25 million Series A purchasing agreement. This investment supports the advancement of Alzamend 's clinical trial and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman emphasized the company's dedication to advancing clinical milestones and revolutionizing lithium-based therapies for millions affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.who.int/health-topics/mental-health#tab=tab_2 Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 06, 2024 09:00 AM Eastern Daylight Time

Image

Consumer

COMCAST RISE AWARDS GRANT PACKAGES TO 100 SOUTHERN COLORADO SMALL BUSINESSES

COMCAST RISE, A NATIONAL INITIATIVE TO SUPPORT AND STRENGTHEN SMALL BUSINESSES, AWARDS ANOTHER 100 HOUSTONIANS WITH COMPREHENSIVE GRANT PACKAGES

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

Back to School Ready 2024

Anthony Milewski Unveils Monthly Newsletter for Mastering Market Speculation

THE WORLD’S FIRST IMMERSIVE GAMING EXPERIENCE TO LAUNCH SECOND HOUSTON LOCATION THIS AUGUST

The Highly Anticipated NILU Hypercar has Arrived!

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

Headline